
--- Page 1 ---
page 1 / 2 copy No. Date: Examination: Histopathological examination Examination No.: Internal invoice No. Value of diagnostic procedure Age: Gender: F Patient: XXX /es-0-3 Material: Total organ resection -st br 8523/3 Unit in charge: Central Operating Theatre Physician in charge:. CQLF: rontr' caunns, ductnl,P4pr1/ny_8503/2 Material collected on: : Material received on: Site: bust,nos c5o.9 Expected time of examination: 5 working days w 4/15 Clinical diagnosis:. Examination performed on: Macroscopic description: RagWwattstzed 21 x 17 x 5 cm removed without axillary tissues with a skin flap of 19 x 8.5 cm. Weight 700 g. Tumour sized 2.2 x 1,9 x 2.4 cm in the upper outer quadrant, located 2.1 cm from the upper boundary, 0.7 cm from the base and. 1.5 cm from the skin.. Microscopic description: Carcinoma mucinosum partim ductale invasivum - NHG2 (3 + 2 + 1/21 mitoses/10 HPF - visual area 0.55 mm). Foci of carcinoma ductale in situ Dcis found within the tumour (solid and cribrate type, with medium nuclear atypia and comedo necrosis 2% of the tumour). Lesions in situ of the type carcinoma intraductale mamillae.. Lesions in situ of the type mastopathia fibrosa et cystica in the glandular texture.. AXILLARY LYMPH NODES Sinus histiocytosis in tymphonodo (No I). Iest result  Final diagnosis to be given after .examination Compliance validated by: Examination performed on: Results of immunohistochemical examination:. Estrogen receptors found in over 75% neoplastic cell nuclei. Progesterone receptors found in over 75% neoplastic cell nuclei.. HER2 protein stained with by . . Negative reaction in invasive cancerous cells ( Score = 0) Compliance validated by: Examination performed on: UUID:D3EA3547-7E53-442E-A957-B2DD7EBAFBB9 Reda icted

--- Page 2 ---
Examination: Histopathological examination page 2 / 2 Examination No.: Patient: xXX Gender: F Examination performed on Histopathological Diagnosis: (including examination Carcinoma mucinosum partim ductale invasivum et ductale in situ mammae dextrae Jnvgstye mutinous andin part ductal! (coranans snd ductsh in situ canrelnorna of the right breast:y (NHG2, pT2, pN0/sn/) Compliance validated by: CONTACT YOUR DOCTOR WITH THIS REPORT!

--- Page 3 ---
TCGA Pathologic Diagnosis Discrepancy Form Instructions: The TcGA Pathologic Diagnosis Discrepancy Form should be completed when the pathologic diagnosis!.. documented on the mitial pathology.report for'a case submitted for TcGA isinconsistent with the diagnosis provided on the:. Case Quality Control Form completed for the submitted case:: .... Tissue Source Site (TSS):. TSS Identifier:  TSS Unique Patient Identifier:. Completed By (Interviewer Name : Completed Date: Diagnosis Information. :: ... . :..: B. Data Element Entry Alternatives Working Instructions  Provide the diagnosis/ histologic subtype(s) documented on  Pathologic Diagnosis the initial pathology report for this case. If the histology for Provided on Initial Pathology Report Histologic features of "Ductal partiaily papilary Provide the histologic features selected on the TCGA Case the sample provided Quality Control Form completed for this case. for TCGA, as reflected on the CQCF. Discrepancy between Pathology Report and Case Quality Control Forrn.:  Provide the reason for DRcweyQucyy daty  Provide a reason describing why the diagnosis on the initial.  the discrepancy  pathology report for this case is not consistent with the  between the pathology  diagnosis selected on the TCGA Case Quality Control Form. report and the TCGA due to Case Quality Control Form.  Name of Tss Reviewing Pathologist or e name of the pathologist who reviewed this cas for TCGA.  Biorepository Director 1 acknowledge that the above informatlon provided by my institution is true and correct and has been quality controlled. TSs Reviewing Pathologist or Biorepository Director. Date I acknowledge that the above information provided by my instibstion is true and correct and has been quality controlied. The Attending Pathologist or the Department Chairman has been informed or is aware of the above diserepancy In diagnoses.. Principal Investigator Signature Date